Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-05-23 Transaction in Own Shar…
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
Informativa sul programma di acquisto di azioni proprie di DiaSorin S.p.A. - Periodo 13/05/2022 - 23/05/2022
Transaction in Own Shares Classification · 98% confidence The document is titled "INFORMATIVA SETTIMANALE SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE DI DIASORIN S.P.A." (Weekly Information on the Share Buyback Program of DiaSorin S.p.A.). It details the number of own shares purchased during a specific period (May 13, 2022, to May 23, 2022) and provides a detailed transaction log. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares' (POS). Although it is a report detailing the transaction, it is not a general regulatory filing (RNS) or a report publication announcement (RPA) because it contains the substantive data required for this specific corporate action disclosure, rather than just announcing that a report is available.
2022-05-23 Italian
DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay
Regulatory Filings Classification · 99% confidence The document is a formal announcement from DiaSorin, dated May 20, 2022, regarding the CE marking of a new diagnostic assay (ARIES® Flu A/B & RSV+SARS-CoV-2 Assay). The header indicates it is 'Informazione Regolamentata' (Regulated Information) received by Euronext Milan. The content describes a product development/regulatory milestone and includes quotes from management. This type of announcement, detailing a specific operational or product update that is material to investors but does not fit neatly into standard financial reports (like 10-K, ER, or IR), is best classified as a general Regulatory Filing or Announcement. Since it is not a dividend notice, management change, director dealing, or earnings release, and it is not explicitly a presentation (IP) or a transcript (CT), the most appropriate general category for a specific, non-standard regulatory disclosure is RNS (Regulatory Filings). The document length (5235 chars) is substantial enough that it is the report itself, not just a notice of publication (RPA).
2022-05-20 English
DiaSorin annuncia la marcatura CE del test molecolare ARIES® Flu A/B & RSV+SARS-CoV-2
Environmental & Social Information Classification · 99% confidence The document is a formal announcement from DiaSorin, dated May 20, 2022, regarding receiving the CE mark for a new molecular test (ARIES® Flu A/B & RSV+SARS-CoV-2). The structure, including 'Informazione Regolamentata' headers, 'Oggetto' (Subject), and the explicit statement 'Vedi allegato' (See attachment) followed by the detailed press release content, strongly suggests this is a regulatory disclosure intended for immediate public release, rather than a comprehensive periodic report (like 10-K or IR) or a transcript. Since it announces a specific, non-financial corporate event (product regulatory approval) and is structured as a formal market communication, it fits best under the general 'Regulatory Filings' category (RNS) as a catch-all for significant, non-standard announcements, or potentially an Earnings Release (ER) if it were financial, but here it is product/regulatory news. Given the context of Italian regulated information ('Informazione Regolamentata'), RNS is the most appropriate general regulatory filing code when a more specific code like 'CAP' (financing) or 'LTR' (legal) does not apply. It is not an ER because it focuses on product approval, not financial results.
2022-05-20 Italian
Pubblicazione del verbale dell'assemblea degli azionisti del 29 aprile 2022
AGM Information Classification · 99% confidence The document is a short regulatory announcement (3574 characters) dated May 11, 2022, with the subject line 'Pubblicazione del verbale dell'assemblea degli azionisti del 29 aprile 2022' (Publication of the minutes of the shareholders' meeting of April 29, 2022). The text explicitly states that the minutes ('verbale') of the shareholders' meeting held on April 29, 2022, have been made available to the public on the company website. This fits the definition of a Report Publication Announcement (RPA) because it announces the availability of another document (the meeting minutes) rather than being the minutes themselves. The AGM Information (AGM-R) code is for the presentation materials, and the minutes themselves are not explicitly covered, making RPA the best fit based on the 'MENU VS MEAL' rule.
2022-05-11 Italian
Verbale Assemblea Ordinaria degli Azionisti 29 aprile 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document text contains detailed tables listing 'Azionisti Rilevanti' (Relevant Shareholders) with share counts and voting rights percentages, followed by detailed voting results for specific agenda items, such as 'Punto 1.1 della parte Ordinaria dell'ordine del giorno' concerning the approval of the 'Bilancio di esercizio al 31 dicembre 2021' (Financial Statements for the year ended December 31, 2021). The subsequent pages show extensive lists of shareholder names and their votes ('Voti'). This structure—presenting shareholder composition and detailed voting outcomes on financial statement approval—is characteristic of the minutes or official results of a General Meeting. Since the document explicitly details the voting results for the approval of the annual financial statements and includes a breakdown of votes by shareholder, it strongly indicates the official record of the Annual General Meeting (AGM) proceedings or the declaration of those results. Given the options, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most precise fit for a document detailing the outcome of shareholder votes on resolutions, even though it relates to the AGM.
2022-05-11 English
Update Annual Calendar of Corporate Events 2022
Report Publication Announcement Classification · 99% confidence The document is a formal announcement from DiaSorin S.p.A. regarding an 'Update Annual Calendar of Corporate Events 2022'. It specifically details the scheduled dates for the approval of the 'Half-Yearly Financial Report' and the 'Third Quarter 2022 results'. This type of communication, which announces the timing of future financial report releases, aligns best with the definition of a Report Publication Announcement (RPA). It is not the report itself (like an IR or 10-K), but an announcement about when those reports will be published. The short length (3432 chars) and the nature of the content support this classification, adhering to the 'MENU VS MEAL' rule.
2022-05-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.